Why the study?
Indian patients with HFpEF present younger with distinct comorbidity burdens compared to Western populations, creating challenges for existing management strategies and necessitating India-specific guidance.
Population
25 HF experts from India and Europe
Design
Modified Delphi consensus process
Key result
Finerenone reduced the incidence of the primary composite endpoint of kidney failure, sustained eGFR decline ≥40%, or renal death by 18% (HR 0.82) compared to placebo in patients with chronic kidney disease and type 2 diabetes.
Authors
Loading...
Supports phenotype-based HFpEF care in India; extends global recommendations with region-specific guidance.
RCT (n=5,674)
Double-blind
Randomized
Yes
Hazard Ratio: 0.82 (95% CI 0.73–0.93)
Absolute Event Rate: 17.8% vs 21.1%
p-value: p=0.001
This expert consensus provides India-specific, phenotype-based recommendations for the diagnosis and management of HFpEF, emphasizing SGLT2 inhibitors, MRAs, and GLP-1 RAs.
Seth et al. (2026) conducted an RCT in Chronic kidney disease associated with type 2 diabetes (n=5,674). Finerenone vs. Placebo was evaluated on Composite of kidney failure, sustained eGFR decline ≥40% or renal death (HR 0.82, 95% CI 0.73-0.93, p=0.001). Finerenone reduced the incidence of the primary composite endpoint of kidney failure, sustained eGFR decline ≥40%, or renal death by 18% (HR 0.82) compared to placebo in patients with chronic kidney disease and type 2 diabetes.